Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

Gayathri Anandappa; Michael J. Overman

doi:10.1016/j.xcrm.2022.100908

Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

Gayathri Anandappa, Michael J. Overman

GI Medical Oncology

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.¹ By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.

Original language	English (US)
Article number	100908
Journal	Cell Reports Medicine
Volume	4
Issue number	1
DOIs	https://doi.org/10.1016/j.xcrm.2022.100908
State	Published - Jan 17 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.xcrm.2022.100908

Cite this

@article{98f84cc7cc874047bac063826f404097,

title = "Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer",

abstract = "In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.1 By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.",

author = "Gayathri Anandappa and Overman, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2022",

year = "2023",

month = jan,

day = "17",

doi = "10.1016/j.xcrm.2022.100908",

language = "English (US)",

volume = "4",

journal = "Cell Reports Medicine",

issn = "2666-3791",

publisher = "Cell Press",

number = "1",

}

TY - JOUR

T1 - Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

AU - Anandappa, Gayathri

AU - Overman, Michael J.

PY - 2023/1/17

Y1 - 2023/1/17

N2 - In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.1 By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.

AB - In a recent issue of Cancer Cell, Amodio and colleagues report an interesting method of modulating immunosurveillance in colorectal tumors with DNA mismatch repair (MMR) heterogeneity.1 By pharmacologically enriching the MMR deficient (MMRd) component using 6-thioguanine, they demonstrate improved tumor control in murine models.

UR - http://www.scopus.com/inward/record.url?scp=85146308678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146308678&partnerID=8YFLogxK

U2 - 10.1016/j.xcrm.2022.100908

DO - 10.1016/j.xcrm.2022.100908

M3 - Comment/debate

C2 - 36652917

AN - SCOPUS:85146308678

SN - 2666-3791

VL - 4

JO - Cell Reports Medicine

JF - Cell Reports Medicine

IS - 1

M1 - 100908

ER -

Harnessing the therapeutic vulnerability of MMR heterogeneity in colorectal cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this